ライフサイエンスコーパス: cytomegalovirus infection

1 val, graft function, and incidence of AR and cytomegalovirus infection.

2 sign of new drugs for the treatment of human cytomegalovirus infection.

3 stomy, long-term mechanical ventilation, and cytomegalovirus infection.

4 on beyond the immediate-early phase of human cytomegalovirus infection.

5 venous ganciclovir treatment for symptomatic cytomegalovirus infection.

6 coenzyme A reductase inhibitor use and prior cytomegalovirus infection.

7 em also developed superimposed rejection and cytomegalovirus infection.

8 y long-term, memory-like responses to murine cytomegalovirus infection.

9 or prevent other systemic manifestations of cytomegalovirus infection.

10 stinal dysmotility as a consequence of acute cytomegalovirus infection.

11 daches, posttransplant diabetes, and chronic cytomegalovirus infection.

12 significantly higher incidence of antecedent cytomegalovirus infection.

13 ischemic events and incidence of antecedent cytomegalovirus infection.

14 not essential for the IFN response to human cytomegalovirus infection.

15 haematogenous liver and lung metastasis, and cytomegalovirus infection.

16 s early as fetal life, such as in congenital cytomegalovirus infection.

17 immunologic memory to secondary exposures to cytomegalovirus infection.

18 K) cells are key mediators in the control of cytomegalovirus infection.

19 imilar incidence of neutropenia and reported cytomegalovirus infection.

20 K cell function in vivo in response to mouse cytomegalovirus infection.

21 pregnancies complicated by congenital human cytomegalovirus infection.

22 or up to six 4-week cycles at doses used for cytomegalovirus infection.

23 defective in protecting the host from mouse cytomegalovirus infection.

24 served after Listeria monocytogenes or mouse cytomegalovirus infection.

25 expansion of Ly49H(+) NK cells during mouse cytomegalovirus infection.

26 of viral-induced proliferation during murine cytomegalovirus infection.

27 9 to 2.88; p = .001) as high as that without cytomegalovirus infection.

28 thelial cells, an important cell type during cytomegalovirus infection.

29 ure death of endothelial cells during murine cytomegalovirus infection.

30 mphasis on the study of postnatally acquired cytomegalovirus infection.

31 ovirus in breast milk will acquire a primary cytomegalovirus infection.

32 r agents such as valganciclovir for treating cytomegalovirus infection.

33 re 15 infections in 12 patients, including 5 cytomegalovirus infections.

34 ir were also less likely to have extraocular cytomegalovirus infections (0, vs. 10.3 percent in the t

35 aft loss (0 vs. 6), patient death (0 vs. 3), cytomegalovirus infection (15% vs. 12%), and 1-year seru

36 us leukaemia relapse (20%vs 7%, p=0.009) and cytomegalovirus infection (28%vs 17%, p=0.023) than was

37 nary tract infection (3/7), hematuria (3/7), cytomegalovirus infection (3/7), and immunosuppression w

38 ce of infection (pneumonia, 19.0% vs. 26.1%; cytomegalovirus infection, 9.5% vs. 26.1%; and sepsis, 2

39 Most evidence suggests that early cytomegalovirus infection accelerates HIV disease progre

40 confidence interval [CI], 1.08-34.86), prior cytomegalovirus infection (adjusted OR, 5.65; 95% CI, 0.

41 In one patient with recurrent cytomegalovirus infections, administration of IL-2 parti

42 Control of cytomegalovirus infection after allo-BMT was also impair

43 rotects mice from retinitis caused by murine cytomegalovirus infection after supraciliary inoculation

44 s for VL in renal transplant recipients were cytomegalovirus infection after transplantation (odds ra

45 Cytomegalovirus infection after transplantation and livi

46 Seven (11.7%) patients experienced cytomegalovirus infection, all of whom responded to trea

47 ymphocytic choriomeningitis virus and murine cytomegalovirus infections also induced this trafficking

48 ffer significantly was a higher incidence of cytomegalovirus infection among patients with chronic he

49 d in 47% of patients, with 4 presenting with cytomegalovirus infection and 4 (age, 42-59 years) diagn

50 gs offer a new physiopathologic link between cytomegalovirus infection and allograft dysfunction in r

51 Cytomegalovirus infection and bacterial infection occurr

52 sitivity, posttransplantation HCV treatment, cytomegalovirus infection and center, female sex was an

53 igorously initiates and amplifies the active cytomegalovirus infection and cooperates with activated

54 Underlying liver disease, cytomegalovirus infection and disease, portal vein throm

55 DC), and natural killer (NK) cells to murine cytomegalovirus infection and found distinct functions a

56 nologic complications of transfusion such as cytomegalovirus infection and graft-versus-host disease.

57 nses and plasma cell expansion during murine cytomegalovirus infection and modestly restrains immune

58 CpG1) allele are highly susceptible to mouse cytomegalovirus infection and show impaired infection-in

59 is at the highest risk for developing active cytomegalovirus infection and to determine its effects o

60 d in two nongenetic models of iron overload (cytomegalovirus infection and treatment with ferric ammo

61 elial cells only in patients who experienced cytomegalovirus infection and were more frequent within

62 s, toxoplasmosis, other infections, rubella, cytomegalovirus infection, and herpes simplex virus infe

63 more than one factor (liver transplantation, cytomegalovirus infection, and rifampin use) when compar

64 One route by which cytomegalovirus infections are acquired in newborns is v

65 of regulation was found in vivo with murine cytomegalovirus infection as a physiologic model of NK c

66 psis trials should consider including active cytomegalovirus infection as a prospective covariate.

67 uly ineffective; they showed that imbalanced cytomegalovirus infection between arms would cause false

68 ith an imbalance on the proportion of active cytomegalovirus infection between study arms could lead

69 The G1 arrest introduced by cytomegalovirus infection blocks S-phase entry after ser

70 Four patients (13%) developed cytomegalovirus infection, but none had tissue-invasive

71 products also diminishes the transmission of cytomegalovirus infections by that route.

72 Congenital toxoplasmosis (CT) and cytomegalovirus infection (cCMV) may cause significant m

73 Risk factors, such as acute rejection and cytomegalovirus infection, contribute to the development

74 y was performed using the Spanish Congenital Cytomegalovirus Infection Database.

75 In mice, systemic murine cytomegalovirus infection decreased serum erythropoietin

76 dy reveals how protection and disease during cytomegalovirus infection depend on viral strain and dos

77 These results suggest that the outcome of cytomegalovirus infection depends on the presence of oth

78 organ-transplant recipients with persistent cytomegalovirus infection developed morphologic abnormal

79 rapidity and extent to which drug resistant cytomegalovirus infection develops has been elucidated.

80 agents, older donor age, posttransplantation cytomegalovirus infection, elevated very low density lip

81 LA matching, immunosuppression regiments and cytomegalovirus infection, heterotopic heart transplanta

82 patients early rejection occurred in 13 and cytomegalovirus infection in 5.

83 cidofovir to placebo for prophylaxis against cytomegalovirus infection in hematopoietic cell transpla

84 Human cytomegalovirus infection in individuals lacking a fully

85 ted and increase in frequency in response to cytomegalovirus infection in mice.

86 ver, recent studies have demonstrated active cytomegalovirus infection in nonimmunosuppressed intensi

87 pathway offers full protection against mouse cytomegalovirus infection in the absence of the other.

88 Human cytomegalovirus infection in the presence of the cyclin-

89 ere was no excess incidence of malignancy or cytomegalovirus infection in this prolonged follow-up pe

90 e documented in 11 patients (15%), including cytomegalovirus infection in three patients (4%).

91 Human cytomegalovirus infection in transplant recipients has b

92 n this study, we investigated the effects of cytomegalovirus infection in Trp53 heterozygous mice.

93 diators of NK cell-mediated control of mouse cytomegalovirus infection in vivo.

94 ication, were dependent on AIM2 during mouse cytomegalovirus infection in vivo.

95 flammatory drugs might help to control human cytomegalovirus infections in conjunction with other ant

96 ldom of consequence in healthy term infants, cytomegalovirus infections in low-birth-weight premature

97 ograft vasculopathy progression and reducing cytomegalovirus infections in maintenance heart transpla

98 ler (NK) cells are crucial in the control of cytomegalovirus infections in mice and humans.

99 arize recent studies of breast-milk-acquired cytomegalovirus infections in newborns, particularly in

100 It has been suggested that cytomegalovirus infection increases the risk of ischemic

101 nt hepatitis), and cryptococcal (symptomatic cytomegalovirus infection) infections.

102 velopment of a vaccine to prevent congenital cytomegalovirus infection is a major public health prior

103 Because cytomegalovirus infection is a risk factor for invasive

104 One common sign of human cytomegalovirus infection is altered liver function.

105 of intrinsically more aggressive disease; 3) cytomegalovirus infection is associated with earlier ons

106 Cytomegalovirus infection is present in the majority of

107 d high disease severity, in whom the rate of cytomegalovirus infection is up to 36%.

108 Cytomegalovirus infection is very common and leads to th

109 During murine cytomegalovirus infections known to target spleen and li

110 Cytomegalovirus infections located in posterior eye segm

111 Prenatal cytomegalovirus infection may cause pregnancy complicati

112 We hypothesize that active cytomegalovirus infection may confound survival outcomes

113 Our data support the concept that cytomegalovirus infection may drive NK-cell development

114 -line use of brincidofovir for prevention of cytomegalovirus infection may preserve downstream option

115 mbalanced proportion of patients with active cytomegalovirus infection may severely compromise the re

116 Lastly, in MZ twins discordant for cytomegalovirus infection, more than half of all paramet

117 in cells with viral inclusions diagnostic of cytomegalovirus infection, not tumor as the thallium SPE

118 after cessation of IS and no tissue-invasive cytomegalovirus infections occurred.

119 Active cytomegalovirus infection occurs frequently in nonimmuno

120 Human cytomegalovirus infection of colon-cancer cells (Caco-2)

121 Human cytomegalovirus infection of human fibroblasts induces t

122 Rhesus cytomegalovirus infection of rhesus macaques has emerged

123 Human cytomegalovirus infection of the developing central nerv

124 liver pathology was evaluated during murine cytomegalovirus infections of mice.

125 The effect of human cytomegalovirus infection on cellular DNA synthesis in h

126 The effects of cytomegalovirus infection on HIV-exposed infants are poo

127 munosuppression, and infection, specifically cytomegalovirus infection, on the development of chronic

128 he transcriptional level during acute murine cytomegalovirus infection or after repetitive polyinosin

129 roportion of lung transplants that developed cytomegalovirus infection or disease during the 180-day

130 cant differences were found in occurrence of cytomegalovirus infection or disease, Pneumocystis carin

131 sociated with basiliximab and no evidence of cytomegalovirus infection or posttransplant lymphoprolif

132 The incidence of cytomegalovirus infection (P<.05) and posttransplant dia

133 rosing cholangitis (P=0.009) and symptomatic cytomegalovirus infection (P=0.008).

134 ificant increase in the frequency of primary cytomegalovirus infection (P=0.045), and a decrease in c

135 NAemia was not significantly associated with cytomegalovirus infection (P=0.937).

136 (P=0.0053), cold storage time (P=0.019), and cytomegalovirus infections (P=0.002).

137 leading to opportunistic infections such as cytomegalovirus infection, periocular nerve involvement

138 Human cytomegalovirus infection perturbs multiple cellular pro

139 Gaps remain in understanding the role that cytomegalovirus infection plays in HIV-exposed infants.

140 In other specimens, preservation injury, cytomegalovirus infection, post-transplant lymphoprolife

141 nt (PAK or PTA [vs. SPK], RR=3.02, P=0.002), cytomegalovirus infection posttransplant (RR=2.41, P=0.0

142 variety of clinical manifestations of human cytomegalovirus infection probably results from both vir

143 uinone oxido-reductase), we found that human cytomegalovirus infection protected cells from rotenone-

144 Both cytomegalovirus infection rates (BD 21% vs. ED 8%, P=0.0

145 than groups A (37%) or B (23%) (P < 0.001); cytomegalovirus infection rates were 35%, 20% and 23%, r

146 Although the incidence of cytomegalovirus infection remained unchanged, a signific

147 ta in the literature suggest that congenital cytomegalovirus infection remains a research priority, b

148 lymphocytic choriomeningitis virus or murine cytomegalovirus infections resulted in profound splenic

149 Viral disease, particularly cytomegalovirus infection, results in significant morbid

150 the localization of IE1 and IE2 during human cytomegalovirus infection, suggesting a principle common

151 ctive advantages during in vivo responses to cytomegalovirus infection, suggesting that receptor dens

152 n the setting of a short-term (4-day) murine cytomegalovirus infection, terminally differentiated NKs

153 t day 90) were more likely to have had prior cytomegalovirus infection than those with early-onset as

154 viously been demonstrated that, during human cytomegalovirus infection, the viral IE2 86 and IE2 40 p

155 rmal clearance of Listeria monocytogenes and cytomegalovirus infections, the mice displayed a profoun

156 the active recruitment of neutrophils during cytomegalovirus infection, thereby providing for efficie

157 , deceased donor, early rejection, and early cytomegalovirus infection to estimate hazard ratios for

158 We use a mouse model of cytomegalovirus infection to show that, like T cells, NK

159 In the AMR cohort, two cases of cytomegalovirus infection, two cases of BK virus infecti

160 c immunomonitoring and routine screening for cytomegalovirus infection until discharge from the inten

161 verall mortality rate associated with active cytomegalovirus infection was 1.93 times (95% CI, 1.29 t

162 The overall rate of active cytomegalovirus infection was 17% (95% confidence interv

163 Incidence of cytomegalovirus infection was 4.2% at 12 months, and 99.

164 In allogeneic patients, active human cytomegalovirus infection was associated with HHV-6 isol

165 Cell cycle progression during cytomegalovirus infection was investigated by fluorescen

166 ion by activated NK cells in an acute murine cytomegalovirus infection was significantly reduced desp

167 The rates of cytomegalovirus infection were significantly lower in th

168 ces of histologic hepatitis C recurrence and cytomegalovirus infection were similar in each group.

169 at hepatitis B, and cidofovir, used to treat cytomegalovirus infections) were alleviated by the early

170 imics the outcome seen in humans with latent cytomegalovirus infection, where reactivation of virus o

171 the mother increases the rate of congenital cytomegalovirus infection, while maternal antiretroviral